as of 11-20-2026 3:59pm EST
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.3B | IPO Year: | 2024 |
| Target Price: | $18.00 | AVG Volume (30 days): | 754.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.60 - $17.50 | Next Earning Date: | 11-10-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 261.16% | Revenue Growth (next year): | 3.65% |
| P/E Ratio: | -10.78 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Nov 10, 2026
2 frnm-20260930xexx991.htm
Document
Freenome Reports Third Quarter 2026 Financial Results
– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –
– Entered the public market and raised gross proceeds of $310 million –
BRISBANE, Calif. (Nov. 10, 2026) — Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to optimize single- and multi-cancer blood tests, today reported its financial results for the third quarter ended September 30, 2026, and provided guidance for 2026.
Third Quarter Financial Highlights
•Total revenue was $183.5 million for the third quarter of 2026, driven primarily by $180.0 million recognized under our collaboration and license agreement following FDA approval of SimpleScreen CRC, compared to $1.0 million for the third quarter of 2025.
•License and collaboration revenue was $182.5 million, and service and other revenue was $0.9 million for the third quarter of 2026.
•GAAP net income was $60.1 million for the third quarter of 2026, compared to a GAAP net loss of $64.5 million for the third quarter of 2025.
•Went public on the Nasdaq Capital Market on July 21, 2026, under the ticker symbol FRNM, having raised approximately $310 million in gross proceeds from top healthcare investors.
•Cash, cash equivalents and marketable securities totaled $430.0 million as of September 30, 2026.
•Net cash provided by operating activities was $38.4 million for the third quarter of 2026.
•Adjusted EBITDA, a non-GAAP financial measure, was $117.9 million for the third quarter of 2026, compared to negative $56.3 million for the corresponding period in 2025. See “Non-GAAP Financial Measures” below.
•Completed the conversion of approximately $50.5 million of principal and accrued interest under the Abbott convertible note into approximately 3.4 million shares at $15.00 per share. Upon the closing of the business combination in July 2026, the Roche convertible note was converted into approximately 6.4 million shares at $12.00 per share.
Recent Operating Highlights
•Received FDA approval on July 24, 2026, for SimpleScreen™ CRC, a blood-based screening test for adults 45 and older at average risk for colorectal cancer, triggering a $100 million milestone payment under Freenome’s collaboration and exclusive U.S. commercial license agreement with Exact Sciences (assumed by Abbott after acquisition).
•Reported topline results from an updated version of SimpleScreen™ CRC. The study met all primary and secondary endpoints and showed improved detection of advanced precancerous lesions, including lesions with high-grade dysplasia.
•Under the commercial license agreement, the Freenome-developed SimpleScreen™ CRC test was launched by Abbott on September 30, 2026 in the United States.
•Subsequent to quarter-end in October, expanded the Personalized Cancer Detection (PCD) portfolio with the launch of SimpleScreen™ Lung and the option to add SimpleScreen CRC in a single blood draw, for individuals eligible for both screenings. SimpleScreen Lung is a protein-based laboratory-developed screening test for adults ages 50 to 80 with a significant smoking history who are not currently participating in guideline-recommended screening.
•Received FDA Breakthrough Device Designation for the multiomics version of the SimpleScreen Lung test that is currently being developed.
•Advanced development of the AI-powered multiomics discovery platform for the PCD pipeline, with the next two single-cancer readouts anticipated in December and our first asymptomatic multi-cancer detection readout in mid 2027.
“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation,” said Aaron Elliott, Ph.D., CEO of Freenome. “With SimpleScreen CRC approved by the FDA and our lung program advancing, we remain focused on expanding access to blood-based early cancer detection. Looking ahead, we believe the opportunity is substantial as our multiomics AI platform positions us to build a portfolio of single-cancer and multi-cancer tests that has the potential to truly transform how cancer is detected.”
Three Months Ended September 30, (Unaudited)Nine Months Ended September 30, (Unaudited)
Revenue ($ in thousands)20262025% 20262025%
License and Collaboration $182,547 $— 100 %$187,702 $— 100 %
Service and Other $942 $1,035 (9)%$2,283 $2,530 (10)%
Total Revenue$183,489 $1,035 17,628 %$189,985 $2,530 7,409 %
Third Quarter 2026 Financial Results
For the three months ended September 30, 2026, total revenue was $183.5 million, compared to $1.0 million for the same period in 2025, an increase of $182.5 million. License and Collaboration revenue was $182.5 million, compared to none in 2025. Service and Other revenue was $0.9 million, compared to $1.0 million in 2025.
Total operating costs and expenses were $11
See how FRNM stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "FRNM Freenome Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.